Xiaoxiang Z Zhu

US Patent:

7973057, Jul 5, 2011

Filed:

Sep 17, 2004

Appl. No.:

10/572485

Inventors:

Nigel H. Greig - Phoenix MD, US
Harold Holloway - Middle River MD, US
Arnold Brossi - Bethesda MD, US
Xiaoxiang Zhu - North Brunswick NJ, US
Tony Giordano - Shreveport LA, US
William D. Figg - Fairfax VA, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC
P2D Inc. - Cincinnati OH

International Classification:

A01N 43/40
A61K 31/445

US Classification:

514323, 546201, 546221, 514183

Abstract:

Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-α) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.

US Patent:

8546430, Oct 1, 2013

Filed:

Jun 3, 2011

Appl. No.:

13/153355

Inventors:

Nigel H. Greig - Phoenix MD, US
Harold Holloway - Middle River MD, US
Arnold Brossi - Bethesda MD, US
Xiaoxiang Zhu - North Brunswick NJ, US
Tony Giordano - Shreveport LA, US
William D. Figg - Fairfax VA, US

Assignee:

P2D, Inc. - Cincinnati OH

International Classification:

A01N 43/40
A61K 31/445

US Classification:

514323, 546201, 546221, 514183

Abstract:

Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-α) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.

US Patent:

20040067991, Apr 8, 2004

Filed:

Sep 15, 2003

Appl. No.:

10/332115

Inventors:

Nigel Greig - Phoenix MD, US
Mark Mattson - Bel Air MD, US
Xiaoxiang Zhu - North Brunswick NJ, US
Harold Holloway - Middle River MD, US

International Classification:

A61K031/428

US Classification:

514/367000

Abstract:

This invention relates generally to tetrahydrobenzothiazole analogues and tetrahydrobenzooxyzole analogues, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to methods of treatment using these compounds. The invention also encompasses pharmaceutically acceptable esters, amides, and salts of such compounds. The invention further provides a method of reducing or delaying apoptosis in a population of cells, comprising contacting the population of cells with a tetrahydrobenzothiazole analogue or a tetrahydrobenzooxyzole analogue, thereby reducing or delaying apoptosis in the population of cells.

US Patent:

20050130972, Jun 16, 2005

Filed:

Nov 12, 2004

Appl. No.:

10/988428

Inventors:

Jian-Qiang Fan - Demarest NJ, US
Xiaoxiang Zhu - North Brunswick NJ, US
Kamlesh Sheth - North Brunswick NJ, US

International Classification:

A61K031/501
A61K031/454
C07D043/02
A61K031/50
A61K031/445

US Classification:

514247000, 514326000, 514328000, 514252010, 544238000, 544239000, 546207000

Abstract:

The present invention provides novel hydroxy piperidine (HP) derivatives having (i) a positive charge at the position corresponding to the anomeric position of a pyranose ring; (ii) a short, flexible linker emanating from the corresponding position of the ring oxygen in a pyranose; and (iii) a lipophilic moiety connected to the linker and pharmaceutically acceptable salts thereof. The linker can be absent if the lipophilic moiety corresponds to a hydrocarbon chain with a linear length of 6 or more carbons. The present invention further provides a method for treating individuals having Gaucher disease by administering the novel HP derivative as “active-site specific chaperones” for the mutant glucocerebrosidase associated with the disease.

US Patent:

20050137223, Jun 23, 2005

Filed:

Nov 12, 2004

Appl. No.:

10/988427

Inventors:

Jian-Qiang Fan - Demarest NJ, US
Xiaoxiang Zhu - North Brunswick NJ, US
Kamlesh Sheth - North Brunswick NJ, US

International Classification:

C07D471/02
A61K048/00
A61K031/4745

US Classification:

514303000, 546118000, 564123000, 514044000

Abstract:

The present invention provides glucoimidazole (GIZ) and polyhydroxycyclohexenyl amine (PHCA) derivatives, methods of making them, and methods of use where the GIZ and PHCA derivatives have a short, flexible linker emanating from the corresponding position of the ring oxygen in a pyranose; and a lipophilic moiety connected to the linker and pharmaceutically acceptable salts thereof. More particularly, the present invention further provides a method for treating individuals having Gaucher disease by administering the novel GIZ or PHCA derivatives as “active-site specific chaperones” for the mutant glucocerebrosidase associated with the disease.

US Patent:

20060264467, Nov 23, 2006

Filed:

May 17, 2006

Appl. No.:

11/440473

Inventors:

Benjamin Mugrage - Cranbury NJ, US
Gary Lee - Cranbury NJ, US
Xiaoxiang Zhu - Cranbury NJ, US
Robert Boyd - Cranbury NJ, US
Kamlesh Sheth - Cranbury NJ, US

International Classification:

A61K 31/445

US Classification:

514317000, 514326000, 514327000

Abstract:

The present invention provides a method for increasing the activity of a mutant or wild-type α-glucosidase enzyme in vitro and in vivo by contacting the enzyme with a specific pharmacological chaperone which is a derivative of 1-deoxynojirimycin. The invention also provides a method for the treatment of Pompe disease by administration of chaperone small molecule compound which is a derivative of 1-deoxynojirimycin. The 1-deoxynojirimycin derivative is substituted at the N or C1 position. Combination therapy with replacement α-glucosidase gene or enzyme is also provided.

US Patent:

20080319032, Dec 25, 2008

Filed:

Nov 13, 2007

Appl. No.:

11/939515

Inventors:

Nigel H Greig - Phoenix MD, US
Mark Mattson - Bel Air MD, US
Xiaoxiang Zhu - North Brunswick NJ, US
Harold Wayne Holloway - Middle River MD, US

International Classification:

A61K 31/428
C12N 5/00
C07D 277/68
A61K 31/423
A61P 3/10
A61P 25/00
C07D 263/58

US Classification:

514367, 435375, 548170, 548221, 548222, 514375

Abstract:

This invention relates generally to tetrahydrobenzothiazole analogues and tetrahydrobenzooxyzole analogues, to pharmaceutical compositions which include these compounds and a pharmaceutically acceptable carrier, and to methods of treatment using these compounds. The invention also encompasses pharmaceutically acceptable esters, amides, and salts of such compounds. The invention further provides a method of reducing or delaying apoptosis in a population of cells, comprising contacting the population of cells with a tetrahydrobenzothiazole analogue or a tetrahydrobenzooxyzole analogue, thereby reducing or delaying apoptosis in the population of cells.

US Patent:

20100189708, Jul 29, 2010

Filed:

Apr 8, 2010

Appl. No.:

12/756382

Inventors:

Jian-Qiang Fan - Demarest NJ, US
Xiaoxiang Zhu - North Brunswick NJ, US
Kamlesh Sheth - North Brunswick NJ, US

Assignee:

AMICUS THERAPEUTICS, INC. - Cranbury NJ

International Classification:

A61K 31/45
A61K 38/47
A61K 31/7088
A61P 43/00

US Classification:

424 9461, 514315, 514 44 R

Abstract:

The present invention provides novel hydroxy piperidine (HP) derivatives having (i) a positive charge at the position corresponding to the anomeric position of a pyranose ring; (ii) a short, flexible linker emanating from the corresponding position of the ring oxygen in a pyranose; and (iii) a lipophilic moiety connected to the linker and pharmaceutically acceptable salts thereof. The linker can be absent if the lipophilic moiety corresponds to a hydrocarbon chain with a linear length of 6 or more carbons. The present invention further provides a method for treating individuals having Gaucher disease by administering the novel HP derivative as “active-site specific chaperones” for the mutant glucocerebrosidase associated with the disease.